We've heard how the use of drugs like Ozempic can drive weight loss, as well as potentially boost heart health and cut out ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Consumers may cycle on and off GLP-1 medications because of financial constraints. These consumers present opportunities for ...

FROM sulphur burps to diarrhoea, we’re all familiar with the brutal side effects of fat jabs – but have you heard of ‘Ozempic ...

Here are five key things investors need to know to start the trading day: Stocks rose Friday, wrapping up one of the most ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Ryan Rasmussen was determined to lose weight so he would be around to ski and spend time with his wife and children.

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

GLP-1s like Ozempic, as well as weight-loss surgery, are among the recommendations to treat childhood obesity in the first guideline update in Canada in almost 20 years.

India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, ...